We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Agentes biológicos aprobados y en desarrollo clínico para el tratamiento de la dermatitis atópica.
- Authors
Otero Torres, S.; Serra Baldrich, E.; Padullés Zamora, N.; Suárez-Lledó Grande, A.; Santacana Juncosa, E.; Comas Sugrañes, D.
- Abstract
Atopic dermatitis (AD) is a chronic, multifactorial, pruritic, inflammatory disease affecting the skin. Studies relating to its physiopathology have made it possible to develop biopharmaceuticals that act on cytokines and other mediators involved in the pathogenesis of AD. At present, dupilumab has been approved for use in Europe and the USA in cases of moderate-to-severe AD in adults that are candidates for systemic treatment. There are biological agents in clinical development which have therapeutic objectives based on the pathogenesis of AD, with some of these agents showing promising results.
- Publication
El Farmacéutico Hospitales, 2020, Issue 217, p10
- ISSN
0214-4697
- Publication type
Academic Journal